The disclosure relates to a pharmaceutical composition suitable for preventing or reducing niacin-induced flushing, wherein the pharmaceutical composition comprises: niacin microparticles having a pH-dependent release profile, and aspirin microparticles having a pH-independent release profile, wherein the niacin microparticles have a reduced capacity to provoke a cutaneous flushing reaction in a subject wherein the aspirin microparticles are present in an amount effective to reduce the cutaneous flushing caused by the niacin wherein there is a lag time between release of aspirin and release of niacin following administration of the composition and wherein the amount of aspirin in the composition is between 80 mg and 500 mg that is released based on an aspirin release profile, wherein about 70% to 90% of aspirin AUC is released over a period of time of 2 to 16 hours following administration of the composition, or wherein the aspirin concentration in plasma is greater than 5% of Cmax over a period of time of 2 to 16 hours following administration of the composition. These pharmaceutical compositions are suitable for preventing or reducing niacin-induced flushing.
